

<ion-view title="Acerca de ICapp" id="page7">

    <div class="bar bar-subheader cal-4">
        <h2 class="title negro">Bibiografía Organización IC</h2>
    </div>

    <ion-content padding="false" class="has-header" >
        <div class="spacer" style="width: 300px; height: 40px;"></div>

        <div style="padding: 20px;" class="bibliografia">
            <ol>
                <li>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 May 20. pii: ehw128. [Epub ahead of print]. </li>
                <li>Yancy CW; Jessup M; Bozkurt B; Butler J, Casey, DE Jr, Drazner MH; et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013;62:e147-239. </li>
                <li>Kengne AP. The Framingham Study, Diabetes Mellitus and Cardiovascular Disease: Turning Back the Clock. Prog Cardiovasc Dis 2010;53:45-51. </li>
                <li>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality intype 2 diabetes. N Engl J Med 2015;373:2117-28. </li>
                <li>Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials Eur J Heart Fail. 2016 Jan 28. doi: 10.1002/ejhf.473. [Epub ahead of print]. </li>
                <li>Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failureand iron deficiency. Eur Heart J 2015;36:657-68. </li>
                <li>Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210-19. </li>
                <li>O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD et al Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010;56:692-99. </li>
                <li>Giannetta E, Feola T, Gianfrilli D, Pofi R, Dall'Armi V, Badagliacca R et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med 2014;12:185. </li>
                <li>Zhang W. EULAR evidence-based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65: 1312-24. </li>
                <li>Angermann C, Pia M, Erdmann E, Levy P, Simonds AK, Somers VK et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015;373:1095-105. </li>
                <li>Comín-Colet J, Enjuanes C, Lupón J et al. Transitioins of care between acute and chronic heart failure: critical steps in the design of a multidisciplinary care model for the prevention of repeat hospital admissions. Rev Esp Cardiol.2016. doi: 10.1016/j.rev.2016.05.001 </li>
            </ol>
        </div>

        <div class="spacer" style="width: 300px; height: 20px;"></div>

    </ion-content>


</ion-view>
